ALLUVI: A COMPREHENSIVE INVESTIGATION INTO RETATRUTIDE'S POTENTIAL

Alluvi, known as BI 4744, offers a significant breakthrough in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable results in clinical studies, potentially surpassing current GLP-1 site activator